Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.0952W HIGH $3.44
Volume
20.02 K
Value Traded
10.47 K
Short % Float
1.5%
+0.46%Week
+0.92%1 Month
-3.93%3 Month
-5.58%6 Month
-86.28%5 Year
-89.43%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
67.07 M
EPS (TTM)
-1.48
P/E Ratio
-
Ent. Value
-42.45 M
Total Shares
30.47 M
Float Shares
23.07 M
Insiders
24.33%
Institutions
6.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XBIT Catalyst Timeline
Dated clinical, regulatory and corporate events for XBiotech Inc.
Past FDA Catalysts and PDUFA Decisions
How XBIT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C41 / 100
Pipeline Score
$157M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
2.3x
rNPV / MCap
Top 37%
Micro Cap(rank 244 of 658)
Percentile Rank
XBiotech Inc. carries a moderate pipeline score (41/100), with $626M risk-adjusted pipeline value, led by vilamakitug in Axial Spondyloarthritis (Phase 2), across $67B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| vilamakitug Small moleculeNCT06526377 | Axial Spondyloarthritis | Phase 2 | NOT YET_RECRUITING | 150 | Sep 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every XBIT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SIMARD JOHNDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 2,470,355 3,840,736 held | $0.00 | 01/03/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in XBIT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in XBIT for Q2 2026. | ||||
XBIT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XBIT ranks across every disease it competes in
Competitive Position is a premium feature
See how XBIT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXBIT News
XBITXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
XBiotech has announced the successful completion of the FDA's 30-day review of its IND application for the Phase II V-SPINE study, which will evaluate vilamakitug in patients with active axial spondyloarthritis. The study aims to enroll 150 participants and assess the drug's efficacy and safety. This marks a significant step in addressing the unmet medical needs in this patient population.
Read more →XBITXBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
XBiotech has announced the successful FDA review of its IND application for the V-SPINE study, a Phase II trial evaluating vilamakitug in patients with active axial spondyloarthritis. The study will involve 150 participants and aims to assess the drug's efficacy and safety. The trial is set to proceed with patient recruitment in the U.S., marking a significant step in XBiotech's rheumatology program.
Read more →XBITXBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis
XBiotech Inc. has announced the FDA's approval of its IND application for the V-SPINE Phase II study, which will evaluate the efficacy and safety of Vilamakitug in treating active axial spondyloarthritis. The study will involve 150 participants and aims to determine the percentage achieving an ASAS40 response by week 16. This marks a significant step in XBiotech's rheumatology program.
Read more →XBIT▼ -29.5%on this news· ran to -40% by day 3
XBiotech Pauses Rheumatology program
XBiotech has announced a pause in its rheumatology clinical program following the results of a Phase II study for rheumatoid arthritis, which did not meet its primary endpoint. The study faced significant irregularities, complicating the interpretation of the findings. As a result, the company will halt further studies in arthritis and related areas while it evaluates the implications of these results.
Read more →XBIT▼ -13.2%on this news· ran to -25% by day 3
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech's Phase 1/2 study of Natrunix in combination with ONIVYDE and 5-FU shows promising results for advanced pancreatic cancer. The treatment demonstrated reduced toxicities and improved patient outcomes, including a notable decrease in severe adverse events and hospitalization. While the findings suggest a potential breakthrough, the small sample size and statistical significance warrant cautious interpretation.
Read more →XBITXBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
XBiotech Inc. has announced plans to construct a new R&D facility on its 48-acre campus in Austin, Texas. The four-story building will support the company's commercialization efforts for its Natrunix rheumatology program and will include wet laboratories for infectious disease research. Construction is set to begin in the first quarter of 2024, with a focus on minimizing ecological impact through a subterranean parking garage.
Read more →XBITDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
XBiotech has appointed Dr. Alan Kivitz as Lead Investigator for its Natrunix program targeting rheumatoid arthritis. The Phase II study is currently enrolling patients and aims to assess Natrunix's efficacy in combination with methotrexate. Dr. Kivitz's expertise in rheumatology is expected to enhance the trial's success as the company anticipates positive outcomes.
Read more →XBITXBiotech Announces Outcome of EMA's Oral Explanation Meeting
XBiotech Announces Outcome of EMA's Oral Explanation Meeting AUSTIN, Texas, April 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that the European Medicines Agency (EMA) rendered a negative "trend" vote after meeting with the Company to discuss the "Day
Read more →XBITCorporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity
Corporate Presentation 2016 NASDAQ: XBIT Creating Breakthrough Therapies from Natural Human Immunity 1 This presentation contains forward - looking statements, including declarations regarding management's beliefs and expectations,that involve substantial risks and uncertainties
Read more →XBITXBiotech Closes Initial Public Offering Austin, TX
XBiotech Closes Initial Public Offering Austin, TX April 17, 2015 XBiotech Inc. (NASDAQ: XBIT), a leading developer of next-generation therapeutic antibodies, announced today the closing of its initial public offering of 4,000,000 shares of its common stock at an initial public
Read more →About XBiotech Inc.
Headquarters5217 WINNEBAGO LANE, AUSTIN, TX, 78744
BIOPHARMAWATCH ELITE PLUS
Trade the next XBIT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime